Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Gliclazide
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Gliclazide 120mg/5ml oral suspension
0601021M0AAAIAI
|
Gliclazide | Gliclazide | Endocrine System | No data available |
|
Gliclazide 160mg/5ml oral suspension
0601021M0AAAJAJ
|
Gliclazide | Gliclazide | Endocrine System | No data available |
|
Gliclazide 20mg/5ml oral suspension
0601021M0AAANAN
|
Gliclazide | Gliclazide | Endocrine System | No data available |
|
Gliclazide 30mg/5ml oral suspension
0601021M0AAAPAP
|
Gliclazide | Gliclazide | Endocrine System | No data available |
|
Gliclazide 50mg/5ml oral suspension
0601021M0AAAHAH
|
Gliclazide | Gliclazide | Endocrine System | No data available |
|
Gliclazide 60mg/5ml oral suspension
0601021M0AAAGAG
|
Gliclazide | Gliclazide | Endocrine System | No data available |
|
Glimil 80mg tablets
0601021M0BEAAAA
|
Glimil | Gliclazide | Endocrine System | No data available |
|
Nazdol MR 30mg tablets (Consilient Health)
0601021M0BFAAAM
|
Nazdol | Gliclazide | Endocrine System | No data available |
|
Nazdol MR 30mg tablets (Mylan)
0601021M0BFABAM
|
Nazdol | Gliclazide | Endocrine System | No data available |
|
Nazdol MR 30mg tablets (Teva)
0601021M0BFACAM
|
Nazdol | Gliclazide | Endocrine System | No data available |
|
Vitile XL 30mg tablets
0601021M0BJAAAM
|
Vitile | Gliclazide | Endocrine System | No data available |
|
Vivazide 80mg tablets
0601021M0BDAAAA
|
Vivazide | Gliclazide | Endocrine System | No data available |
|
Xywin 30mg modified-release tablets
0601021M0BRAAAM
|
Xywin | Gliclazide | Endocrine System | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.